Back
Aligos Therapeutics Quote, Financials, Valuation and Earnings
America's enemies are regrouping & it may sucker punch your savings
Click here to learn more.
Buy
55
ALGS
Aligos Therapeutics
Last Price:
18.29
Seasonality Move:
0%
7 Day Trial
ALL ACCESS PASS
$
7
"This Changes Everything" - Trump Hands Millions Massive IRS Gift
Learn More HereAligos Therapeutics Price Quote
$18.29
+0.09 (+-1.14%)
(Updated: November 21, 2024 at 4:56 AM ET)
Aligos Therapeutics Key Stats
Buy
55
Aligos Therapeutics (ALGS)
is a Buy
Day range:
$17.88 - $19.85
52-week range:
$6.76 - $30.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
18.28
P/B ratio:
1.44%
Volume:
471.8K
Avg. volume:
407.3K
1-year change:
1.42%
Market cap:
$72.2M
Revenue:
$15.5M
EPS:
$-17.11
How Much Does Aligos Therapeutics Make?
-
How Much Are Aligos Therapeutics's Sales Annually?
ALGS Revenues are $15.5M -
How Much Profit Does Aligos Therapeutics's Make A Year?
ALGS net income is -$87.7M
Is Aligos Therapeutics Growing As A Company?
-
What Is Aligos Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.61% -
What Is Aligos Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Aligos Therapeutics Stock Price Performance
-
Did Aligos Therapeutics Stock Go Up Last Month?
Aligos Therapeutics share price went up by 151.03% last month -
Did ALGS's Share Price Rise Over The Last Year?
ALGS share price rose by 1.42% over the past 1 year
What Is Aligos Therapeutics 52-Week High & Low?
-
What Is Aligos Therapeutics’s 52-Week High Share Price?
Aligos Therapeutics has traded as high as $30.00 over the past 52 weeks -
What Is Aligos Therapeutics’s 52-Week Low Share Price?
Aligos Therapeutics has traded as low as $6.76 over the past 52 weeks
Aligos Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Aligos Therapeutics?
-
How Much Debt Does Aligos Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Aligos Therapeutics Have?
Cash and short term investments quarterly total is $74.9M -
What Is Aligos Therapeutics’s Book Value Per Share?
Book value per share is 15.07
Is Aligos Therapeutics Cash Flow Positive?
-
What Is ALGS Cash Flow From Operations?
Cash flow from operations (TTM) is -$85M -
What Is Aligos Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $88.2M -
What Is Aligos Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$38.3M
Aligos Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
ALGS return on invested capital is -118.75% -
What Is Aligos Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -68.4% -
What Is ALGS Return On Equity?
ROE is a measure of profitability and is -118.75%
Aligos Therapeutics Earnings Date & Stock Price
-
What Is Aligos Therapeutics's Stock Price Today?
A single share of ALGS can be purchased today for 18.20 -
What Is Aligos Therapeutics’s Stock Symbol?
Aligos Therapeutics trades on the nasdaq under the ticker symbol: ALGS -
When Is Aligos Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Aligos Therapeutics is scheduled on March 12, 2025 -
When Is ALGS's next ex-dividend date?
Aligos Therapeutics's next ex-dividend date is November 21, 2024 -
How To Buy Aligos Therapeutics Stock?
You can buy Aligos Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Aligos Therapeutics Competitors
-
Who Are Aligos Therapeutics's Competitors?
Below is a list of companies who compete with Aligos Therapeutics or are related in some way:
Aligos Therapeutics Dividend Yield
-
What Is ALGS Dividend Yield?
Aligos Therapeutics’s dividend yield currently is 0% -
What Is Aligos Therapeutics’s Payout Ratio?
Aligos Therapeutics’s payout ratio is 0% -
When Did Aligos Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 21, 2024 -
What Is Aligos Therapeutics’s Dividend Per Share?
Aligos Therapeutics pays a dividend of $0.00 per share
Aligos Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -131.7% |
| Revenue: | -60.82% | 280.7% |
Analyst Recommendations
| Buy Recommendations: | 1 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 103.33 |
| Upside from Last Price: | 467.77% |